At Ablantis, The goal is to reduce malaria mortality rate to 0
and attain malaria elimination by 2025.
NATIONAL MALARIA STRATEGY GOAL
The Goal

It threatens the population of the Federal Republic of Nigeria and kills nearly half a million people every year, Most of them are infants under the age of 5 and pregnant women.

The Goal

At least 80% (154,055,568 people) of fever patients attending health facilities to receive a diagnostic test.

The Goal

At least 80% (154,055,568 people) of fever/malaria patients will receive appropriate and timely treatment according to the national treatment guideline

The Goal

At least 100% of pregnant women attending A.N. services and 50% of all pregnant women receive  at least two doses of Intermittent Preventive Therapy.

36Reach-out states
95Infant Mortality Reduction Rate
25000Job Opportunities
48Total elimination period in months
OUR MISSION is to help national
malaria elimination by taking certain measures which are:
Application of Lavicides

The lavicide will be applied to breeding areas such as small bodies of water, catch basins, ponds, lakes, ditches, rice fields, drainages etc.

Utilization of test and treatment packs

The project will utilize approximately 100 million test and cure packs, and 400 million mosquito lavicide briquettes

Advantages

The tests and drugs are less cumbersome, and more effective than the conventional methods of testing and treating malaria

Advantages

The lavicide works immediately upon deployment providing control for a full 150 days

Job Creation

With the aid of the Federal Government, the project will create 150,000 part time jobs and 25,000 permanent jobs

Advantages

Our elimination taskforce will be deployed across the country in every state, every quarter for effective elimination

Advantages

The ITTCL project will touch the lives of every Nigerian, even those in the most remote parts of the country in collaboration with the Federal Government.

Advantages

The project uses a 3 step approach to attack the menace that is malaria; By using a rapid malaria diagnostic test and  also the latest in WHO approved combination therapy  (ACT)

Malaria Testing, Treatment and Elimination

Advantages of testing?
  • Reduction in Artemisinin combination therapy ACT wastage (most fevers are not malaria)
  • No impact on mortality from non-malarial febrile illness (misdiagnosis)     
  • Avoidance of Accelerated development of Artemisinin resistance (there are no alternatives to the ACTs)
  • Credibility of health workers and health service
Who are we testing?

Ablantis will use a 3-Step approach to attack the menace that is malaria; Using a rapid malaria diagnostic test and also the latest in World Health Organisation  (WHO) approve combination therapy (ACT)  for different categories:

  • ADULTS
  • INFANTS
  • CHILDREN, AGED BETWEEN 3-7 YEARS OLD
  • JUNIORS, AGED BETWEEN 7-15
  • PREGNANT WOMEN
Why are we treating?

The essence of the treatment is to bridge the gap between those with access to ACTs and those without access, especially infants and children between the ages of 3 – 7

Who are we treating?
  • Over 13 years to Adults
  • 6 Years to 13 years
  • 1 Years to 5 years
  • Infants (6 Months to 2 years)
  • Pregnant women
Advantages of the ITTCL Project

With proper treatment these burdens will be curbed to an all time low:

  • Nigeria shoulders ~ ¼  of the world’s malaria burden, with an estimated 120 million cases per year
  • Malaria is endemic in Nigeria, with 97% (186,792,376 people) of the population at risk of infection
  • Stable/perennial transmission in all parts of the country
  • A total of approximately 300,000 malaria deaths annually
  • Malaria in pregnancy accounts for 11% of maternal mortality.
  •  Malaria is responsible for 25% of all infant-related mortality and 30% of mortality in children under five years of age.